Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Quentin30on May 10, 2023 11:07am
231 Views
Post# 35440727

wow what an AGM

wow what an AGMSo detailed, completely blew me away...  I loved the question and answer session too...  line after line of imvestors asking questions, and the management team went out of their way to paint a picture of certain future success...

well, we can all dream can't we... another presentation, and ONCY is declining again...

From all the recent Q&As however, it is most apparent that ONCY will not be going ahead with a CPI until a partner can see clear evidence of differentiation of OS between the doublet and triplet... We're only now at the stage where ONCY is duplicating the results of IND-213. That is excellent news anyway, but they still need someone to fund the phase III... OR they (WE) wait another 9 months until Q1 2024, to know if it is even worth adding a CPI.

I agree with others commentary here and other boards that ONCY is signalling that they will be going for a PIII without a CPI. Pretty much all patients on the triplet would still have to be alive as of now in order to think adding a CPI was worth it... so sorry folks, but we've wasited 5 years since IND-213 to say, yep, the results were valid... what a sh& tshow.

<< Previous
Bullboard Posts
Next >>